The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Do tumor infiltrating lymphocytes (TILs) predict benefits from trastuzumab therapy for HER2 positive breast cancer? Meta-analysis of individual patient data from 4097 women in 5 trials.
 
Robert Kerrin Hills
No Relationships to Disclose
 
Rosie Bradley
No Relationships to Disclose
 
Jeremy Braybrooke
No Relationships to Disclose
 
Richard G. Gray
No Relationships to Disclose
 
Hannah Taylor
No Relationships to Disclose
 
Carsten Denkert
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Lilly; Molecular Health; MSD Oncology; Roche
Research Funding - German Breast Group (Inst); Myriad Genetics (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - Patent WO2010076322A1; Patent WO2015114146A1; Patent WO2020109570A1; VMScope digital pathology software
 
Sunil S. Badve
Honoraria - Bristol Myers Squibb Foundation; Dako/Agilent Technologies; Personalis; Ventana Medical Systems
Consulting or Advisory Role - Agilent; BMS; PAIGE.AI; Ventana Medical Systems
Speakers' Bureau - Agilent; Genomic Health; Targos GmbH
Research Funding - Bristol Myers Squibb Foundation (Inst); Dako/Agilent Technologies (Inst); Lilly (Inst)
Patents, Royalties, Other Intellectual Property - E-Score for predicting recurrence of DCIS (Inst); EarlyR - signature for ER+ breast cancer (Inst)
 
Rim S. Kim
No Relationships to Disclose
 
Magali Lacroix-Triki
Honoraria - AstraZeneca; Daiichi Sankyo Pharmaceutical; MSD; Roche
 
Meredith M. Regan
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Debiopharm Group (Inst); Ipsen (Inst); Tersera; Tolmar
Research Funding - AstraZeneca (Inst); Bayer (Inst); bioTheranostics (Inst); Bristol-Myers Squibb (Inst); Debiopharm Group (Inst); Ipsen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); TerSera (Inst)
 
Daniel F. Hayes
Stock and Other Ownership Interests - InBiomotion
Honoraria - Tempus
Consulting or Advisory Role - BioVica; Cellworks; Cepheid; Epic Sciences; Exact Sciences; Freenome; Guardant Health; L-Nutra; Macrogenics; Oncocyte; Predictus Biosciences; Tempus; Turnstone Bio; xilis
Research Funding - AstraZeneca (Inst); Cepheid/Danaher (Inst); Menarini Silicon Biosystems (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Circulating Tumor Cell Capturing Techniques and Devices. Patent No.: US 8,951,484 B2. Date of Patent: Feb. 10, 2015. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Diagnosis and Treatment of Breast Cancer. Patent No. US 8,790,878 B2. Date of Patent: Jul. 29, 2014. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Royalties from licensed technology.; Title: A method for predicting progression free and overall survival at each follow-up timepoint during therapy of metastatic breast cancer patients using circulating tumor cells. Patent no. 05725638.0-1223-US2005008602.
Other Relationship - Menarini; UpToDate
(OPTIONAL) Uncompensated Relationships - UpToDate
 
Mitchell Dowsett
Consulting or Advisory Role - AstraZeneca/MedImmune; Besins Healthcare; Lilly; Roche; Rovi
Research Funding - Lilly (Inst)
Patents, Royalties, Other Intellectual Property - AIR-CIS - a molecular profile for predicting sensitivity of breast cancer patients to CDK4/6 inhibitors among patients resistant to an aromatase inhibitor (Inst); Share of royalties from the invention of abiraterone
 
Andrew NJ Tutt
Employment - Institute of Cancer Research
Leadership - Institute of Cancer Research
Stock and Other Ownership Interests - InBiomotion
Honoraria - PAGE Therapeutics (Inst)
Consulting or Advisory Role - American College of Independent Medical Examiners (Inst); AstraZeneca; AstraZeneca; Cancer Panels; EM Partners; GE Healthcare (Inst); Gilead Sciences; Gilead Sciences (Inst); MD Anderson Cancer Center; Merck Serono (Inst); Research to Practice; VJOncology (Inst)
Research Funding - Artios (Inst); AstraZeneca (Inst); Merck KGaA (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - I have i the past and may in the future be in Receipt of payments under my employer (ICR London) Rewards to inventors Scheme associated with patents held by ICR associated with the use of PARP inhibitors in BRCA 1/2 deficient cancers
Expert Testimony - National Institute for Health and Clinical Excellence (Inst)
Travel, Accommodations, Expenses - AstraZeneca
Other Relationship - Breast Cancer Now Charity (Inst); Cancer Research UK (Inst)
(OPTIONAL) Uncompensated Relationships - St Gallen Early Breast Cancer Consensus Conference
 
Richard D. Gelber
Research Funding - AstraZeneca (Inst); Merck (Inst); Novartis (Inst); Roche (Inst)
 
David A. Cameron
Consulting or Advisory Role - Clarity Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Novartis (Inst); Oncolytics (Inst); Pfizer (Inst); Prima BioMed (Inst); Puma Biotechnology (Inst); Research Triangle Institute RTI Health Solutions (Inst); Roche (Inst); Roche (Inst); Samsung Bioepis (Inst); Sanofi (Inst); Seagen (Inst); Synthon (Inst); Zymeworks (Inst); Zymeworks (Inst)
Research Funding - AstraZeneca (Inst); Novartis (Inst); Roche (Inst)
 
Jonas C. S. Bergh
No Relationships to Disclose
 
Sandra M. Swain
Leadership - Seagen
Stock and Other Ownership Interests - SEAGEN
Consulting or Advisory Role - AstraZeneca; Athenex; Aventis Pharma; bioTheranostics; Daiichi Sankyo; Exact Sciences; Genentech/Roche; Jaguar Health; Lilly; Merck; Molecular Templates; Napo Pharmaceuticals; Natera
Research Funding - Genentech (Inst); Kailos Genetics (Inst)
Travel, Accommodations, Expenses - Aventis Pharma; Daichi Sankyo
Other Relationship - AstraZeneca; AstraZeneca; Roche
(OPTIONAL) Uncompensated Relationships - Genentech/Roche
 
Stefan Michiels
Consulting or Advisory Role - Biophytis; IQvia; Kedrion Biopharma; Roche; Sensorion; SERVIER; Yuhan
 
Sherene Loi
Consulting or Advisory Role - Aduro Biotech (Inst); AstraZeneca (Inst); BMS (Inst); Daiichi Sankyo/Lilly (Inst); G1 Therapeutics (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); PUMA Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst); Silverback Therapeutics (Inst); Tallac Therapeutics (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); Novartis (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst); Seagen (Inst)
Other Relationship - Roche Medical writing support
 
Roberto Salgado
Consulting or Advisory Role - AstraZeneca; BMS; Roche
Speakers' Bureau - Exact Sciences
Research Funding - Merck; Puma Biotechnology; Roche
Travel, Accommodations, Expenses - Merck; Roche